Sumitomo Pharma Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Sumitomo Pharma kazanç ve gelirin sırasıyla yıllık 88.7% ve 4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 88.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 4.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

88.7%

Kazanç büyüme oranı

88.7%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	11.8%
Gelir büyüme oranı	4.0%
Gelecekteki özkaynak getirisi	4.5%
Analist kapsamı	Good
Son güncelleme	26 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Sumitomo Pharma (TSE:4506) Has Debt But No Earnings; Should You Worry?

Nov 25

Is There An Opportunity With Sumitomo Pharma Co., Ltd.'s (TSE:4506) 38% Undervaluation?

Sep 12

There's No Escaping Sumitomo Pharma Co., Ltd.'s (TSE:4506) Muted Revenues Despite A 26% Share Price Rise

Aug 16

A Piece Of The Puzzle Missing From Sumitomo Pharma Co., Ltd.'s (TSE:4506) 28% Share Price Climb

Jun 26

Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?

May 13

Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) Revenues

Apr 17

Kazanç ve Gelir Büyüme Tahminleri

TSE:4506 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (JPY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	362,793	6,523	15,800	33,841	8
3/31/2026	362,678	13,224	19,400	38,256	8
3/31/2025	347,007	-6,512	90,751	124,400	8
9/30/2024	342,665	-279,457	-78,396	-62,844	N/A
6/30/2024	329,547	-260,167	-151,893	-136,785	N/A
3/31/2024	314,558	-314,969	-257,623	-241,893	N/A
12/31/2023	330,307	-173,718	-289,603	-275,326	N/A
9/30/2023	388,897	-134,970	-195,585	-192,040	N/A
6/30/2023	471,354	-144,485	-132,356	-131,413	N/A
3/31/2023	555,544	-74,512	11,310	11,937	N/A
12/31/2022	588,228	-8,448	78,665	78,709	N/A
9/30/2022	585,594	12,680	77,510	88,927	N/A
6/30/2022	588,715	82,719	62,735	77,233	N/A
3/31/2022	560,035	56,413	17,745	31,239	N/A
12/31/2021	553,262	32,321	23,680	36,782	N/A
9/30/2021	548,184	55,372	67,806	81,324	N/A
6/30/2021	513,291	42,762	90,302	102,279	N/A
3/31/2021	515,952	56,219	124,795	135,601	N/A
12/31/2020	520,477	67,031	105,325	117,235	N/A
9/30/2020	513,627	47,720	30,439	40,420	N/A
6/30/2020	499,105	52,309	26,399	38,398	N/A
3/31/2020	482,732	40,753	32,777	46,128	N/A
12/31/2019	469,413	52,637	54,091	66,333	N/A
9/30/2019	463,715	51,088	59,844	73,527	N/A
6/30/2019	460,840	40,083	52,584	65,450	N/A
3/31/2019	459,267	48,627	35,797	48,711	N/A
12/31/2018	449,588	42,826	N/A	N/A	N/A
9/30/2018	452,530	46,430	38,414	55,607	N/A
6/30/2018	466,452	54,285	N/A	N/A	N/A
3/31/2018	466,838	53,448	N/A	93,420	N/A
12/31/2017	470,252	50,011	N/A	N/A	N/A
9/30/2017	454,013	52,956	N/A	52,872	N/A
6/30/2017	424,447	35,035	N/A	N/A	N/A
3/31/2017	411,638	28,991	N/A	21,624	N/A
12/31/2016	404,181	30,923	N/A	N/A	N/A
9/30/2016	402,368	22,405	N/A	48,663	N/A
6/30/2016	408,566	27,122	N/A	N/A	N/A
3/31/2016	403,206	24,697	N/A	49,415	N/A
12/31/2015	396,763	19,799	N/A	N/A	N/A
9/30/2015	392,006	16,903	N/A	22,963	N/A
6/30/2015	379,755	15,632	N/A	N/A	N/A
3/31/2015	371,370	15,447	N/A	30,251	N/A
12/31/2014	382,317	19,896	N/A	N/A	N/A
9/30/2014	384,587	23,122	N/A	49,243	N/A
6/30/2014	387,814	21,007	N/A	N/A	N/A
3/31/2014	387,693	20,061	N/A	49,943	N/A
12/31/2013	363,003	12,334	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 4506 önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 0.3% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: 4506 önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: 4506 önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: 4506 şirketinin gelirinin (yıllık 4% ) JP pazarından (yıllık 4.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 4506 şirketinin gelirinin (yıllık 4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 4506 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 4.5 %).

Sumitomo Pharma Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates upgraded to JP¥25.34 loss

Consensus EPS estimates upgraded to JP¥39.20 loss

Price target increased by 14% to JP¥365

Consensus EPS estimates upgraded to JP¥48.57 loss

Consensus EPS estimates upgraded to JP¥77.85 loss

Consensus EPS estimates upgraded to JP¥103 loss

Recent updates

Sumitomo Pharma (TSE:4506) Has Debt But No Earnings; Should You Worry?

Sumitomo Pharma Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025

New major risk - Share price stability

Second quarter 2025 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to JP¥25.34 loss

Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from FTSE All-World Index (USD)

Is There An Opportunity With Sumitomo Pharma Co., Ltd.'s (TSE:4506) 38% Undervaluation?

There's No Escaping Sumitomo Pharma Co., Ltd.'s (TSE:4506) Muted Revenues Despite A 26% Share Price Rise

Consensus EPS estimates upgraded to JP¥39.20 loss

Price target increased by 14% to JP¥365

Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan

Less than half of directors are independent

Sumitomo Pharma Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to JP¥48.57 loss

A Piece Of The Puzzle Missing From Sumitomo Pharma Co., Ltd.'s (TSE:4506) 28% Share Price Climb

Consensus EPS estimates upgraded to JP¥77.85 loss

Consensus EPS estimates upgraded to JP¥103 loss

Sumitomo Pharma Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Full year 2024 earnings: EPS misses analyst expectations

Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?

Price target decreased by 18% to JP¥334

Consensus EPS estimates fall by 21%

Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) Revenues

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024

Price target decreased by 10% to JP¥413

Consensus EPS estimates fall by 24%

Consensus EPS estimates fall by 24%

Consensus EPS estimates fall by 24%

Price target decreased by 7.8% to JP¥442

Consensus EPS estimates fall by 23%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New major risk - Share price stability

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Sumitomo Pharma Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024

Price target decreased by 9.3% to JP¥510

Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

Consensus EPS estimates fall by 10%

Consensus EPS estimates fall by 15%

Price target decreased by 11% to JP¥630

Sumitomo Pharma Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023

Sumitomo Pharma Co., Ltd. (TSE:4506) acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 Diamond 1 and Diamond 2 Clinical Studies Evaluating Ulotaront in Schizophrenia

Consensus EPS estimates fall by 14%

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Revolka Ltd. Announces Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd

HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Consensus EPS estimates fall by 17%

Price target decreased by 10% to JP¥811

Price target decreased by 7.2% to JP¥883

Consensus EPS estimates fall by 26%, revenue upgraded

Sumitomo Pharma Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023

Full year 2023 earnings: EPS misses analyst expectations

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Consensus EPS estimates upgraded to JP¥35.42 loss

Consensus EPS estimates upgraded to JP¥35.42 loss

Upcoming dividend of JP¥7.00 per share at 3.5% yield

Consensus estimates of losses per share improve by 85%

Consensus EPS estimates have been downgraded.

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2023 Results on May 15, 2023